
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

**FORM S-8
REGISTRATION STATEMENT**
*Under
The Securities Act of 1933*

T2 BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation or organization)

20-4827488
(IRS Employer
Identification No.)

**101 Hartwell Avenue
Lexington, Massachusetts 02421**
(Address of principal executive offices) (Zip code)

**T2 Biosystems, Inc. Inducement Award Plan, as amended
T2 Biosystems, Inc. 2014 Incentive Award Plan, as amended and restated**
(Full title of the plans)

**John Sperzel
President and Chief Executive Officer
T2 Biosystems, Inc.
101 Hartwell Avenue
Lexington, Massachusetts 02421
(781) 457-1200**

Copy to:
**Johan V. Brigham
Evan G. Smith
Latham & Watkins LLP
John Hancock Tower, 27th Floor
200 Clarendon Street
Boston, MA 02116
(617) 880-4500**
(Name and address of agent for service)
(Telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the "Securities Act").

CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered	Amount to be Registered(1)	Proposed Maximum Offering Price Per Share	Proposed Maximum Aggregate Offering Price	Amount of Registration Fee
Common Stock, par value \$0.001 per share	1,410,041 shares (2)	\$0.65 (3)	\$916,526.65	\$118.97
Common Stock, par value \$0.001 per share	3,589,959 shares (4)	\$1.59 (5)	\$5,708,034.81	\$740.90
Common Stock, par value \$0.001 per share	6,268,836 shares (6)	\$0.65 (3)	\$4,074,743.40	\$528.90

- (1) Pursuant to Rule 416 under the Securities Act, this registration statement (this "Registration Statement") shall also cover additional shares of the common stock, par value \$0.001 per share ("Common Stock"), of T2 Biosystems, Inc. (the "Registrant") that may become issuable under the T2 Biosystems, Inc. Inducement Award Plan, as amended (the "IAP") and the T2 Biosystems, Inc. 2014 Incentive Award Plan (the "2014 Plan") by reason of any stock split, stock dividend, recapitalization or other similar transaction.
- (2) Represents 1,410,041 shares of Common Stock available for future issuance under the IAP.
- (3) Calculated in accordance with Rule 457(c) and Rule 457(h) of the Securities Act solely for the purpose of calculating the Proposed Maximum Offering Price Per Share, the Proposed Maximum Aggregate Offering Price and the Amount of the Registration Fee, based on the average high and low prices reported on the Nasdaq Global Market for the Common Stock on May 20, 2020.
- (4) Represents shares of Common Stock issuable upon the exercise of stock options outstanding under the IAP.
- (5) Calculated in accordance with Rule 457(h) of the Securities Act solely for the purpose of calculating the Proposed Maximum Offering Price Per Share, the Proposed Maximum Aggregate Offering Price and the Amount of the Registration Fee, based on the weighted average exercise price (rounded to the nearest cent) for outstanding stock options granted pursuant to the IAP.
- (6) Represents (i) 1,268,836 shares of Common Stock available for future issuance under the 2014 Plan and (ii) an additional 5,000,000 shares of Common Stock that may become issuable under the 2014 Plan pursuant to its terms.

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

The information called for in Part I of Form S-8 is not being filed with or included in this Registration Statement (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Commission.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents, which have been filed with the Commission by the Registrant, pursuant to the Exchange Act, are hereby incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

- (a) the Registrant's Annual Report on [Form 10-K](#) for the fiscal year ended December 31, 2019, filed with the Commission on March 16, 2020, as amended by [Form 10-K/A](#) on April 29, 2020; and
- (b) the Registrant's Quarterly Report on [Form 10-Q](#) for the quarter ended March 31, 2020, filed with the Commission on May 11, 2020, as amended by [Form 10-K/A](#) on April 29, 2020; and
- (c) the Registrant's Current Reports on Form 8-K, filed with the Commission on [January 9, 2020](#) and [March 10, 2020](#), [March 25, 2020](#) and [April 8, 2020](#); and
- (d) the description of the Registrant's Common Stock contained in the prospectus included in the Registrant's registration statement on [Form 8-A](#) (File No. 001-36571), filed with the Commission on July 25, 2014, pursuant to the Exchange Act, and any amendment or report filed for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents. Under no circumstances shall any information furnished under Item 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement, except as to specific sections of such statements as set forth therein.

Item 4. Description of Securities.

Not applicable.

Item 5. Interest of Named Experts and Counsel.

None.

Item 6. Indemnification of Directors and Officers.

Section 102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or

approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. As permitted by Section 102 of the General Corporation Law of the State of Delaware, the Registrant has adopted provisions in its amended and restated certificate of incorporation and bylaws that limit or eliminate the personal liability of the Registrant's directors for a breach of their fiduciary duties of care as directors. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to the Registrant or the Registrant's stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

- any breach of the director's duty of loyalty to the Registrant or the Registrant's stockholders;
- any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
- any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or
- any transaction from which the director derived an improper personal benefit.

These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission.

Section 145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. As permitted by Section 145 of the General Corporation Law of the State of Delaware, the Registrant's amended and restated bylaws provide that:

- the Registrant may indemnify our directors, officers and employees, to the fullest extent permitted by the General Corporation Law of the State of Delaware, subject to limited exceptions;
- the Registrant may advance expenses to its directors, officers and employees, in connection with a legal proceeding to the fullest extent permitted by the General Corporation Law of the State of Delaware, subject to limited exceptions; and
- the rights provided in the Registrant's amended and restated bylaws are not exclusive.

The Registrant's amended and restated certificate of incorporation and its amended and restated bylaws provide for the indemnification provisions described above and elsewhere herein. The Registrant has entered into indemnification agreements with each of its directors and officers. These indemnification agreements may require the Registrant, among other things, to indemnify its directors and officers for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any other company or enterprise to which the person provides services at the Registrant's request. The Registrant maintains a general liability insurance policy that covers certain liabilities of directors and officers of the Registrant arising out of claims based on acts or omissions in their capacities as directors or officers.

Item 7. Exemption from Registration Claimed.

Not applicable.

Item 8. Exhibits.

For a list of exhibits, see the Exhibit index in this Registration Statement, which is incorporated herein by reference.

Item 9. Undertakings.

(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling

person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

SIGNATURES

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Lexington, Commonwealth of Massachusetts, on the 27th day of May, 2020.

T2 BIOSYSTEMS, INC.

By: /s/ JOHN SPERZEL

John Sperzel

President and Chief Executive Officer

SIGNATURES AND POWERS OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John Sperzel, Michael Gibbs, or either of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his or her name, place and stead, in any and all capacities, to file and sign any and all amendments, including post-effective amendments, to this Registration Statement with the Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ JOHN SPERZEL</u> John Sperzel	President, Chief Executive Officer and Director (principal executive officer)	May 27, 2020
<u>/s/ JOHN M. SPRAGUE</u> John M. Sprague	Chief Financial Officer (principal financial and accounting officer)	May 27, 2020
<u>/s/ JOHN MCDONOUGH</u> John McDonough	Non-executive Chairman and Director	May 27, 2020
<u>/s/ MICHAEL J. CIMA, PH.D.</u> Michael J. Cima, Ph.D.	Director	May 27, 2020
<u>/s/ JOHN W. CUMMING</u> John W. Cumming	Director	May 27, 2020
<u>/s/ DAVID B. ELSBREE</u> David B. Elsbree	Director	May 27, 2020
<u>/s/ STANLEY N. LAPIDUS</u> Stanley N. Lapidus	Director	May 27, 2020
<u>/s/ SEYMOUR LIEBMAN</u> Seymour Liebman	Director	May 27, 2020
<u>/s/ ADRIAN JONES</u> Adrian Jones	Director	May 27, 2020

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description of Exhibit</u>
3.1	<u>Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 of the Company's Form 8-K (File No. 001-36571) filed with the Commission on August 12, 2014).</u>
3.2	<u>Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Company's Form 8-K (File No. 001-36571) filed with the Commission on August 12, 2014).</u>
4.1	<u>Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-1/A (File No. 333-197193) filed with the Commission on July 28, 2014).</u>
5.1*	<u>Opinion of Latham & Watkins LLP.</u>
23.1*	<u>Consent of BDO USA LLP, independent registered public accounting firm.</u>
23.2*	<u>Consent of Ernst & Young LLP, independent registered public accounting firm.</u>
23.3*	<u>Consent of Latham & Watkins LLP (included in Exhibit 5.1).</u>
24.1*	<u>Powers of Attorney (incorporated by reference to the signature page hereto).</u>
99.1	<u>T2 Biosystems, Inc. Inducement Award Plan, as amended and restated (incorporated by reference to Exhibit 10.2 of the Company's Form 8-K (File No. 001-36571) filed on January 9, 2020).</u>
99.2	<u>Amended and Restated 2014 Incentive Award Plan and form of option agreements thereunder (incorporated by reference to Exhibit 10.2 of the Company's Form 10-K (File No. 001-36571) filed on March 19, 2018).</u>

200 Clarendon Street
 Boston, Massachusetts 02116
 Tel: +1.617.948.6000 Fax: +1.617.948.6001
 www.lw.com

LATHAM & WATKINS LLP

FIRM / AFFILIATE OFFICES
 Beijing Moscow
 Boston Munich
 Brussels New York
 Century City Orange County
 Chicago Paris
 Dubai Riyadh
 Düsseldorf San Diego
 Frankfurt San Francisco
 Hamburg Seoul
 Hong Kong Shanghai
 Houston Silicon Valley
 London Singapore
 Los Angeles Tokyo
 Madrid Washington, D.C.
 Milan

May 27, 2020

T2 Biosystems, Inc.
 101 Hartwell Ave.
 Lexington, Massachusetts 02421

Re: Registration Statement on Form S-8; 11,268,836 shares of T2 Biosystems, Inc. Common Stock, \$0.001 par value per share

Ladies and Gentlemen:

We have acted as special counsel to T2 Biosystems, Inc., a Delaware corporation (the “**Company**”), in connection with the proposed issuance by the Company of up to 11,268,836 shares of common stock of the Company, \$0.001 par value per share (the “**Shares**”), issuable under the under the T2 Biosystems, Inc. 2014 Incentive Award Plan, as amended (the “**2014 Plan**”) and the T2 Biosystems, Inc. Inducement Award Plan, as amended (the “**IAP**”) and together with the 2014 Plan, the “**Plans**”). The Shares are included in a registration statement on Form S-8 under the Securities Act of 1933, as amended (the “**Act**”), filed with the Securities and Exchange Commission (the “**Commission**”) on May 27, 2020 (the “**Registration Statement**”). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related prospectus, other than as expressly stated herein with respect to the issue of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “**DGCL**”), and we express no opinion with respect to any other laws.

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company for legal consideration in excess of par value in the circumstances contemplated by the Plans, assuming in each case that the individual grants or awards under the Plans are duly authorized by all necessary corporate action and duly granted or awarded and exercised in

LATHAM & WATKINS LLP

accordance with the requirements of law and the Plans (and the agreements and awards duly adopted thereunder and in accordance therewith), the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Very truly yours,

/s/ Latham & Watkins LLP

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

T2 Biosystems, Inc.
Lexington, Massachusetts

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our reports dated March 16, 2020, relating to the consolidated financial statements and the effectiveness of T2 Biosystems, Inc.'s internal control over financial reporting appearing in the Company's Annual Report on Form 10-K for the year ended December 31, 2019. Our report contains an explanatory paragraph regarding T2 Biosystems, Inc.'s ability to continue as a going concern. Our report on the effectiveness of internal control over financial reporting expresses an adverse opinion on the effectiveness of T2 Biosystems, Inc.'s internal control over financial reporting as of December 31, 2019.

/s/ BDO USA, LLP

Boston, Massachusetts
May 27, 2020

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Amended T2 Biosystems, Inc. Inducement Award Plan and the Amended and Restated T2 Biosystems, Inc. 2014 Incentive Award Plan of our report dated March 19, 2018, (except for the effects of the adoption of ASU 2016-18 as discussed in Note 2, as to which the date is March 14, 2019) with respect to the consolidated financial statements of T2 Biosystems, Inc. at December 31, 2018 and 2017 included in its Annual Report (Form 10-K) for the year ended December 31, 2019, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

May 27, 2020